Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.
about
Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancerThe role of the EP receptors for prostaglandin E2 in skin and skin cancerAutocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.Cyclooxygenases and lipoxygenases in cancer.Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scaleAssociation of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.Non-steroid anti-inflammatory drugs, prostaglandins, and cancer.Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.Regulation of inflammation by lipid mediators in oral diseases.Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.COX-2 induces lytic reactivation of EBV through PGE2 by modulating the EP receptor signaling pathway.The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR/STAT3 pathway in UVB-exposed mouse skin.Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium.EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
P2860
Q26828414-18EF3882-C00B-4193-9806-AF9C46CD5CDAQ26999707-CCBDEC7D-6D01-4C1D-9266-C4196D0740B3Q34140169-E0F957F3-AC8F-42FB-8B3E-EB656670E7E2Q34224752-0AAD00FE-633A-467F-8277-89B207889DB1Q34494513-6419AD3F-F325-476E-A1F3-6A41F04D4F57Q34705013-3EAB0C64-7F91-4B88-93F3-0C5CAA528569Q34766640-B957B85E-4522-441C-BE11-54291AAD4885Q35144499-8D25A6DF-E6FA-4134-92EE-5238BD726563Q36420170-36815947-3815-4E0F-B423-9408060C472AQ36689177-DB5CAA52-C844-4E13-A0BA-B4D028EE43B3Q36806255-C2841CEA-B299-473B-B3EF-D3EA27D7DEE5Q36940087-06909550-37BB-4AAE-BEFA-C618EB351B3EQ37470737-1F50DF15-1EBD-4423-AE80-3886473E4047Q38899898-949E37D3-8577-44BE-AFAD-A7FEA6FB36A5Q39340968-62D2DB31-90D6-4A84-AB91-E76616BE840FQ40855155-CBE53594-25AC-49A1-96B6-D79CBA88CB29Q42754872-99EC77FE-49D3-464D-8E85-9161425D3E15Q48310988-96DE36FD-F951-47F5-8E82-C98250DC49FCQ55230010-6548D6A1-C691-47AA-8E97-483838861E2F
P2860
Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@ast
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@en
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@nl
type
label
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@ast
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@en
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@nl
prefLabel
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@ast
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@en
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@nl
P2093
P2860
P1476
Prostaglandin E receptor EP1 s ...... rences and cancer disparities.
@en
P2093
Amy M Fulton
Claudia Baquet
Jocelyn Reader
Namita Kundu
Olga B Ioffe
Olga Goloubeva
Phyllis Gimotty
Raymond Konger
Xinrong Ma
P2860
P304
P356
10.1158/1541-7786.MCR-10-0003
P577
2010-09-21T00:00:00Z